Methisoprinol restoration of leukocyte chemotaxis inhibition by blocking factors in immunoproliferative diseases.
The ability of methisoprinol to antagonize the serum-inhibiting activity present in the sera of patients affected by immunoproliferative diseases (Hodgkin's disease and multiple myeloma) was investigated. Using a chemotaxis test, it was found that whereas donor leukocytes preincubated in patient sera exhibited impaired chemotaxis, the presence of methisoprinol (500 micrograms/ml) during the preincubation caused a significant recovery of this leukocyte function. Since the results exclude the assumption of a non-specific stimulation of cell motility, two hypotheses appeared possible for the action of methisoprinol: either an antagonistic activity against the blocking factor at the receptor or the metabolic level, or a direct inactivation of this factor. The clinical implications, with regard to the prophylaxis of infections and a better response to chemotherapy, are discussed.
D000328:Adult; D000368:Aged; D000906:Antibodies; D001667:Binding, Competitive; D002634:Chemotaxis, Leukocyte / Q000187:drug effects*; D005260:Female; D006689:Hodgkin Disease / Q000276:immunology; D006801:Humans; D066298:In Vitro Techniques; D007288:Inosine / Q000031:analogs & derivatives*; D007542:Inosine Pranobex / Q000494:pharmacology*; D007962:Leukocytes / Q000187:drug effects / Q000276:immunology; D008232:Lymphoproliferative Disorders / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000276:immunology; D008258:Waldenstrom Macroglobulinemia / Q000276:immunology
D000906:Antibodies; D007288:Inosine; D007542:Inosine Pranobex